bioAffinity Technologies, Inc. — Director's Dealing 2025

Jan 14, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2025-01-10

Reporting Person: Zannes Timothy P (Secretary, EVP, Gen. Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-10	Common Stock	A	8641	—	Acquired	54765	Direct

Footnotes

F1: Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025.